(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 80.78% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $29,102,000.On average, 6 Wall Street analysts forecast TNXP's revenue for 2026 to be $962,223,899, with the lowest TNXP revenue forecast at $857,208,180, and the highest TNXP revenue forecast at $1,170,557,388. On average, 6 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,939,952,325, with the lowest TNXP revenue forecast at $1,395,990,447, and the highest TNXP revenue forecast at $2,683,277,705.
In 2028, TNXP is forecast to generate $2,954,949,925 in revenue, with the lowest revenue forecast at $1,764,840,370 and the highest revenue forecast at $4,177,989,446.